Takeda defends Entyvio against German conclusion of no added benefit
This article was originally published in Scrip
Executive Summary
Takeda has passionately defended its inflammatory bowel disease drug Entyvio (vedolizumab), after Germany's health technology assessment body IQWiG found that it had no added benefit over standard therapies.